Jeker, Barbara

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2019 | 2018

2019

Prediletto, Irene; Farag, Sarah Ahmed Ibrahim; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bregy, Rachel; Zander, Thilo; Betticher, Daniel; Egger, Thomas; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. Bone marrow transplantation, 54(12), pp. 1923-1925. Nature Publishing Group 10.1038/s41409-019-0508-2

Fassbind, Priska; Jeker, Barbara; Müller, Beatrice Ursula; Bacher, Vera Ulrike; Zimmerli, Stefan; Endrich, Olga; Gahl, Brigitta; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). Improved survival rates of AML patients following admission to the intensive care unit. Leukemia & lymphoma, 60(10), pp. 2423-2431. Taylor & Francis 10.1080/10428194.2019.1594213

Shumilov, Evgenii; Flach, Johanna; Joncourt, Raphael; Porret, Naomi; Wiedemann, Gertrud; Novak, Urban; Gfeller, Eva; Jeker, Barbara; Amstutz, Ursula; Pabst, Thomas; Bacher, Vera (2019). Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML. Leukemia & lymphoma, 60(10), pp. 2588-2590. Taylor & Francis 10.1080/10428194.2019.1585838

Moser, Sebastian; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Betticher, Daniel; Ruefer, Axel; Egger, Thomas; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). Autologous stem cell transfusions on multiple days in patients with multiple myeloma ‐ does it matter? (In Press). Hematological oncology Wiley 10.1002/hon.2673

Ghilardi, Guido; Pabst Müller, Thomas Niklaus; Jeker, Barbara; Müller, Rouven; Cairoli, Anne; Müller, Antonia M S; Bargetzi, Mario; Hitz, Felicitas; Baldomero, Helen; Heim, Dominik; Schmidt, Adrian; Rossi, Davide; Ghielmini, Michele; Wannesson, Luciano; Lerch, Erika; Samaras, Panagiotis; Schanz, Urs; Passweg, Jakob R; Stussi, Georg; Kleber, Martina; ... (2019). Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone marrow transplantation, 54(7), pp. 1029-1037. Nature Publishing Group 10.1038/s41409-018-0379-y

De Santiago de Benito, Alvaro; Jeker, Barbara; Gfeller, Eva; Porret, Naomi; Banz, Yara; Novak, Urban; Bacher, Ulrike; Pabst, Thomas (2019). Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia. (In Press). Haematologica - the hematology journal Ferrata-Storti Foundation 10.3324/haematol.2019.216457

Amsler, Isabel G; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Ulrike; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Luethi, Jean-Marc; Novak, Urban; Pabst Müller, Thomas Niklaus (2019). Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. Leukemia & lymphoma, 60(2), pp. 511-514. Taylor & Francis 10.1080/10428194.2018.1473577

Jeker, Barbara; Pabst Müller, Thomas Niklaus; Novak, Urban (2019). CAR-T-Zelltherapie – eine neue Behandlungsoption. Info@Onkologie, 2019(1), pp. 18-20. Aerzteverlag medinfo AG

Shumilov, Evgenii; Flach, Johanna; Joncourt, Raphael; Porret, Naomi; Wiedemann, Gertrud; Angelillo, Anne; Trümper, Lorenz; Fiedler, Georg Martin; Jeker, Barbara; Amstutz, Ursula; Pabst Müller, Thomas Niklaus; Bacher, Vera Ulrike (2019). Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations. Hematological oncology, 37(3), pp. 319-322. Wiley 10.1002/hon.2603

Shumilov, Evgenyi; Novak, Urban; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Ulrike; Pabst, Thomas (2019). Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients. HemaSphere, 3(2), e176. Wolters Kluwer Health 10.1097/HS9.0000000000000176

Schnell, Bianca R.; Seipel, Katja; Bacher, Ulrike; Jeker, Barbara; Mueller, Beatrice U.; Banz, Yara; Novak, Urban; Pabst, Thomas (2019). Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients. HemaSphere, 3(2), e180. Wolters Kluwer Health 10.1097/HS9.0000000000000180

2018

Moor, Ivana; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Mueller, Beatrice U; Keller, Heinz Peter; Betticher, Daniel; Egger, Thomas; Novak, Urban; Pabst, Thomas (2018). Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma. Bone marrow transplantation, 53(12), pp. 1599-1602. Nature Publishing Group 10.1038/s41409-018-0245-y

Bacher, Vera Ulrike; Porret, Naomi; Joncourt, Raphael; Sanz, Javier; Aliu, Nijas; Wiedemann, Gertrud; Jeker, Barbara; Banz Wälti, Yara; Pabst, Thomas (2018). Pitfalls in the molecular follow up of mutant acute myeloid leukemia. Haematologica - the hematology journal, 103(10), e486-e488. Ferrata-Storti Foundation 10.3324/haematol.2018.192104

Farag, Sarah Ahmed Ibrahim; Jeker, Barbara; Bacher, Vera Ulrike; Mansouri Taleghani, Behrouz; Müller, Beatrice Ursula; Novak, Urban; Pabst Müller, Thomas Niklaus (2018). Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Hematological oncology, 36(4), pp. 671-678. Wiley 10.1002/hon.2546

Gössi, Ursina; Jeker, Barbara; Mansouri Taleghani, Behrouz; Bacher, Vera Ulrike; Novak, Urban; Betticher, Daniel; Egger, Thomas; Zander, Thilo; Pabst, Thomas (2018). Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. Hematological oncology, 36(2), pp. 436-444. Wiley 10.1002/hon.2490

Jeker, Barbara; Novak, Urban; Mansouri Taleghani, Behrouz; Baerlocher, Gabriela M.; Seipel, K; Mueller, B U; Bigler, M; Betticher, D; Luethi, J-M; Farese, S; Ruefer, A; Pabst, Thomas (2018). NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Bone marrow transplantation, 53(2), pp. 175-179. Nature Publishing Group 10.1038/bmt.2017.234

Provide Feedback